THAR vs. ARTL, ALZN, GTBP, KZIA, XCUR, ENSC, EVOK, GOVX, NBY, and SNGX
Should you be buying Tharimmune stock or one of its competitors? The main competitors of Tharimmune include Artelo Biosciences (ARTL), Alzamend Neuro (ALZN), GT Biopharma (GTBP), Kazia Therapeutics (KZIA), Exicure (XCUR), Ensysce Biosciences (ENSC), Evoke Pharma (EVOK), GeoVax Labs (GOVX), NovaBay Pharmaceuticals (NBY), and Soligenix (SNGX). These companies are all part of the "pharmaceutical preparations" industry.
Tharimmune (NASDAQ:THAR) and Artelo Biosciences (NASDAQ:ARTL) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, dividends, risk, earnings, community ranking, valuation and media sentiment.
1.2% of Tharimmune shares are owned by institutional investors. Comparatively, 0.9% of Artelo Biosciences shares are owned by institutional investors. 2.4% of Tharimmune shares are owned by insiders. Comparatively, 6.9% of Artelo Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Artelo Biosciences received 38 more outperform votes than Tharimmune when rated by MarketBeat users.
Tharimmune has a beta of 1.61, meaning that its stock price is 61% more volatile than the S&P 500. Comparatively, Artelo Biosciences has a beta of 1.44, meaning that its stock price is 44% more volatile than the S&P 500.
Artelo Biosciences' return on equity of -73.82% beat Tharimmune's return on equity.
In the previous week, Artelo Biosciences had 9 more articles in the media than Tharimmune. MarketBeat recorded 9 mentions for Artelo Biosciences and 0 mentions for Tharimmune. Artelo Biosciences' average media sentiment score of 0.21 beat Tharimmune's score of 0.00 indicating that Artelo Biosciences is being referred to more favorably in the news media.
Artelo Biosciences has a consensus price target of $5.00, suggesting a potential upside of 252.11%. Given Artelo Biosciences' higher possible upside, analysts clearly believe Artelo Biosciences is more favorable than Tharimmune.
Summary
Artelo Biosciences beats Tharimmune on 9 of the 11 factors compared between the two stocks.
Get Tharimmune News Delivered to You Automatically
Sign up to receive the latest news and ratings for THAR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding THAR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Tharimmune Competitors List
Related Companies and Tools
